

1  
2  
3 **Pre-existing musculoskeletal pain and its association with mortality in newly diagnosed**

4  
5  
6 **comorbid conditions: an electronic health record cohort study**

7  
8  
9  
10  
11  
12  
13  
14 Michelle Marshall<sup>1</sup>; Kayleigh J Mason<sup>1</sup>; John J Edwards<sup>1</sup>; Mamas A Mamas<sup>6</sup>; James Bailey<sup>1</sup>; Neil Heron<sup>1,2</sup>;  
15  
16 Felix A Achana<sup>3</sup>; Martin Frisher<sup>4</sup>; Alyson L Huntley<sup>5</sup>; Christian D Mallen<sup>1</sup>; May Ee Png<sup>3</sup>; Stephen Tatton<sup>1</sup>;  
17  
18 Simon White<sup>4</sup>; Kelvin P Jordan<sup>1</sup>  
19  
20  
21  
22  
23

24 **Affiliations:**

25  
26  
27  
28 1. Centre for Musculoskeletal Health Research, School of Medicine, Keele University, Keele,

29  
30  
31 UK

32  
33  
34 2. Centre for Public Health, Queen's University Belfast, Belfast, UK

35  
36  
37 3. Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK

38  
39  
40 4. School of Pharmacy and Bioengineering, Keele University, Keele, UK

41  
42  
43 5. Centre for Academic Primary Care, Bristol Medical School, Bristol University, Bristol, UK

44  
45  
46 6. Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University,

47  
48  
49  
50 Keele, UK  
51  
52  
53  
54  
55

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Corresponding Author: Dr Michelle Marshall**

[ORCID:0000-0001-8163-6948](https://orcid.org/0000-0001-8163-6948)

[m.marshall@keele.ac.uk](mailto:m.marshall@keele.ac.uk)

David Weatherall Building, Keele University, Keele, ST5 9BG, UK

Downloaded from <https://academic.oup.com/rheumap/advance-article/doi/10.1093/rap/rkad104/7450129> by Keele University user on 11 December 2023

## Abstract

**Objectives:** Musculoskeletal pain is a common risk factor for comorbid conditions and may increase the risk of poor outcomes. The objective was to determine whether patients with pre-existing musculoskeletal pain have an increased mortality risk following a new diagnosis of a comorbid condition.

**Methods:** Patients aged  $\geq 45$  years with a new diagnosis of acute coronary syndrome (ACS), stroke, cancer, dementia, or pneumonia recorded in a UK electronic primary care database linked to hospital and mortality records were examined. The association of mortality with musculoskeletal pain (inflammatory conditions, osteoarthritis [OA], and regional pain) was determined.

**Results:** Sample size varied from 128,649 (stroke) to 406,289 (cancer) by cohort with 22-31% having pre-existing musculoskeletal conditions. In the ACS cohort, there was a higher rate of mortality for all musculoskeletal types. There were also higher unadjusted mortality rates in patients with inflammatory arthritis compared to those without musculoskeletal pain in the stroke, cancer, and dementia cohorts and for patients with OA in the stroke and cancer cohorts. Following adjustment for number of prescribed medications and age, the increased risk of

1  
2  
3 mortality remained only for patients with inflammatory arthritis in the ACS cohort (adjusted HR  
4  
5  
6 1.07; 95% CI 1.03, 1.10).  
7  
8

9  
10 **Conclusion:** Older adults with inflammatory arthritis and OA have increased risk of mortality  
11  
12  
13 when they develop a new condition, which seems to relate to prescribing of multiple medicines.  
14

15  
16 Pre-existing musculoskeletal pain is an indicator of a complex patient who is at risk of poorer  
17  
18  
19 outcomes at the onset of new illnesses.  
20

21  
22 **Keywords:** musculoskeletal pain; mortality; comorbidity; epidemiology; primary care  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Key messages:

- Adults with musculoskeletal pain are at increased risk of mortality from a new comorbid condition.
- Increased mortality was largely explained by them being older and being prescribed more medications.
- This study has highlighted the complexity of patients with severe musculoskeletal pain and new onset condition.

### Lay summary

#### *What does this mean for patients?*

Musculoskeletal pain (pain in the joints and muscles around them) is common and those with pain often have other long-term conditions. We wanted to find out if people with musculoskeletal pain had an increased risk of earlier death following diagnosis of a new serious illness. We studied anonymised healthcare records of patients aged 45 years and over with a new diagnosis of heart attack, stroke, cancer, dementia, or pneumonia. Approximately a third of people with these new diagnoses had a musculoskeletal pain condition including inflammatory arthritis, osteoarthritis, or regional (e.g. back, knee) pain. This group had an increased risk of earlier death compared to those without existing musculoskeletal pain, with the highest risk in those with inflammatory arthritis and osteoarthritis. However, this increased risk was explained by those with musculoskeletal pain being older and on many medications. Taking multiple medicines suggests patients have more illnesses but increases possibility of being on medicines

1  
2  
3 with little benefit or that cause harm, and of not taking medicines as instructed. Doctors need to  
4  
5 consider all of a patient's current illnesses and medicines when treating a new illness. Improving  
6  
7 musculoskeletal pain recognition and management, and regular medicine reviews, may help  
8  
9 improve outcomes of other illnesses.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Musculoskeletal pain is common, with up to one in five adults consulting primary care in the UK for a painful musculoskeletal condition each year and it has a major impact on everyday activity and is a major burden on healthcare systems.(1,2) Musculoskeletal pain commonly co-exists with other conditions and may increase the risk of developing new illnesses. For example, osteoarthritis (OA) (3–5), rheumatoid arthritis (RA) (6–8) and low back pain (9,10) have been shown to be associated with an increased risk of developing heart disease and stroke. Regional pain such as back pain, psoriatic arthritis (PsA), and polymyalgia rheumatica have been linked to the onset of cancer (11–13), OA with dementia (14) and inflammatory musculoskeletal conditions with hospitalisation for community-acquired pneumonia (15). However, it is less clear whether musculoskeletal pain impacts on outcomes of these other conditions. For example, in cardiovascular disease, studies have shown increased in-hospital mortality after acute myocardial infarction, intracranial haemorrhage and ischaemic stroke in patients with RA or systemic lupus erythematosus (16), but other studies have shown no association (17,18) or even reduced mortality in patients with RA (19). Knowledge of the impact of musculoskeletal pain on the prognosis of other conditions would be important in the management of these conditions, and also the management of musculoskeletal pain. The aim of this study was

1  
2  
3 therefore to determine whether pre-existing painful musculoskeletal conditions are associated  
4  
5  
6 with long-term mortality in those with other newly diagnosed conditions and whether this varied  
7  
8  
9 by type of musculoskeletal pain. The study focused on five conditions with evidence of links to  
10  
11  
12 musculoskeletal pain and are amongst the most common reasons for hospitalisation globally.  
13  
14  
15  
16 These index conditions were acute coronary syndrome (ACS), stroke, cancer, dementia, and  
17  
18  
19 community-acquired pneumonia.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Methods

### *Study Design and Setting*

A cohort study using the UK Clinical Practice Research Datalink (CPRD) Aurum database.

CPRD Aurum contains anonymised primary care electronic health records (EHR) for over 40 million patients from over 1,000 general practices using EMIS Web<sup>®</sup> software (20). These data were linked to hospital inpatient admission data from Hospital Episode Statistics (HES), and Office for National Statistics (ONS) Death Registration Data. As the study used anonymised patient electronic health records from CPRD it did not require individual participant consent. The study was approved by the CPRD Independent Scientific Advisory Committee/Research Data Governance (refs 20\_000105 ACS/stroke and 20\_000147 cancer [October 2020 build]; 21\_000504 dementia [June 2021 build] (21); 21\_000689 pneumonia [November 2021 build] (22)). The approved protocols were made available to reviewers.

### *Study Population*

The study population consisted of patients aged 45 years or over with a first ever record of one of our index illnesses and with at least 24 months prior registration at their practice to obtain consultation records for musculoskeletal pain and covariates. For ACS and stroke we included

1  
2  
3 patients with first myocardial infarction or unstable angina, or first stroke or transient ischaemic  
4  
5  
6 attack in their primary care record between 2000 and 2019 and a matching hospital inpatient  
7  
8  
9 record with admission date within 1 month of the primary care recorded date. For cancer we  
10  
11  
12 included patients with a first diagnosis of breast, colon, lung, or prostate cancer in primary care  
13  
14  
15 between 2000 and 2019. We also included patients with a first ever recorded diagnosis of  
16  
17  
18 dementia in primary care between 2005 and 2019. Finally, we included patients with a first ever  
19  
20  
21 recorded bacterial pneumonia diagnosis in primary care, or as the reason for admission to  
22  
23  
24 hospital, between 2014 and 2018. Patients recorded with a pneumonia diagnosis within 2 weeks  
25  
26  
27 after a hospital stay were excluded to ensure pneumonia was not acquired in hospital. Patients  
28  
29  
30 were also excluded if they had a previous record of a viral pneumonia.  
31  
32  
33  
34  
35

36 Diagnoses are recorded in UK primary care using the Read code system up to 2018 and  
37  
38 SNOMED CT codes from 2018. Within hospital admissions, illnesses are recorded using  
39  
40  
41 International Classification of Diseases (ICD-10) codes. Derivation of code lists were based on  
42  
43  
44 those previously developed through a rigorous consensus approach in research studies by  
45  
46  
47 healthcare practitioners, epidemiologists and statisticians with expertise in electronic health  
48  
49  
50 record research at Keele University (11,23,24) and code lists based on those from external  
51  
52  
53 studies using electronic health records. The code lists used for each index condition can be  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 found at <https://eprints.keele.ac.uk/id/eprint/11580/> (25). The date of first diagnosis of the index  
4  
5  
6 condition was defined as that patient's index date.  
7

### 8 9 10 *Outcome*

11  
12  
13  
14 The outcome was all-cause mortality. Patients were followed from their index date until the  
15  
16 earliest of end of their registration at the practice (including death) or last date of collected data.  
17

18  
19  
20 For the ACS and stroke cohorts, those with a death record, end of registration or last data  
21  
22 collection date before thirty days after index date were excluded. For pneumonia, as it is an  
23  
24 acute morbidity, mortality was measured from index date for a maximum of 12 months.  
25  
26  
27

### 28 29 30 *Exposure*

31  
32  
33  
34 Exposure was defined as presence or absence of a painful musculoskeletal condition identified  
35  
36 from primary care records in the 24 months prior to index date. The types of musculoskeletal  
37  
38 pain examined were diagnosed inflammatory conditions (RA, gout, ankylosing spondylitis, giant  
39  
40 cell arteritis, PsA); diagnosed OA; and the most common non-specific regional pains recorded in  
41  
42 primary care (low back pain/backache, knee pain, hip pain, hand/wrist pain).  
43  
44  
45  
46  
47  
48  
49

50  
51 In a secondary analysis, patients with musculoskeletal pain were sub-grouped by severity and  
52  
53 "recency" of pain as an alternative to type. Primary care EHR do not contain direct evidence of  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 pain severity, so we used proxy measures based on: i) a coded referral to a pain management  
4  
5  
6 clinic, rheumatology, orthopaedics, or physiotherapy specialists; or ii) prescription of a strong  
7  
8  
9 analgesic medicine (i.e. a strong opioid such as tramadol, morphine or oxycodone)(26), on the  
10  
11  
12 assumption a referral or stronger analgesic would normally indicate more severe pain. Current  
13  
14  
15 musculoskeletal pain was defined as a recorded consultation for musculoskeletal pain in the six  
16  
17  
18 months before index date. Patients were sub-grouped as: current and severe (recorded  
19  
20  
21 consultation within the six months before index date and either a referral or a prescription of  
22  
23  
24 strong analgesia); current and non-severe; recent (recorded consultation between six and  
25  
26  
27 twenty-four months before index date).  
28  
29  
30

### 31 32 *Covariates*

33  
34  
35  
36 Covariates included in the analyses for all cohorts were: age at index date, gender,  
37  
38  
39 geographical location, race, neighbourhood-level deprivation (Index of Multiple Deprivation,  
40  
41  
42 IMD), year of index consultation, recorded comorbidity in the 24 months prior to the index date  
43  
44  
45 (depression, anxiety or stress; diabetes; other musculoskeletal conditions), general multi-  
46  
47  
48 morbidity based on prescription count (number of different medications prescribed excluding  
49  
50  
51 analgesia) and body mass index, and smoking status recorded in the 60 months prior to the  
52  
53  
54 index date. Cohort-specific covariates were peripheral vascular disease and statin medicine for  
55  
56  
57  
58  
59  
60

1  
2  
3 ACS and stroke, chronic kidney disease for cancer, stroke for dementia, and chronic obstructive  
4  
5  
6 pulmonary disease (COPD), dementia, renal disease, stroke, and type of antibiotic for  
7  
8  
9 pneumonia.

### 13 *Analysis*

16  
17 Binary/categorical patient characteristics were summarised as the number and percentage  
18  
19 within each category and continuous characteristics (index year; age at index date; and number  
20  
21 of prescriptions in the 24 months prior to the index date) were presented using median and  
22  
23 interquartile range (IQR).  
24  
25  
26  
27

28  
29  
30 Analysis of the association of prior musculoskeletal consultation with mortality used flexible  
31  
32 parametric survival models with 3 (ACS; stroke) or 4 (cancer; dementia; pneumonia) degrees of  
33  
34 freedom. Each model was run with only musculoskeletal pain (categorised as none (reference),  
35  
36 regional pain, OA, inflammatory) in the model, progressing to including all covariates.  
37  
38  
39

40  
41  
42 Musculoskeletal pain was included as a time-dependent effect in the fully adjusted models for  
43  
44 cancer, dementia and pneumonia with 4 degrees of freedom for time-dependent effects. All  
45  
46 models included robust standard errors clustered at the practice level. Adjusted hazard ratios  
47  
48  
49  
50 (HR with 95% CI) are presented and, for the ACS, stroke, cancer and dementia cohorts also  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 determined at two, five and ten years of follow-up to assess consistency of association over  
4  
5  
6  
7 time.

8  
9  
10 In the secondary analysis, associations of mortality with recency and severity of musculoskeletal  
11  
12  
13 pain (none; recent; current-non-severe; current-severe) were assessed.  
14  
15

### 16 17 *Sensitivity Analyses*

18  
19  
20 In the main analysis missing data for race, body mass index, smoking status and alcohol status  
21  
22  
23 was recorded as the reference category (white, normal BMI (18.0-24.9 kg/m<sup>2</sup>), never smoked  
24  
25  
26 and does not drink, respectively) with sensitivity analyses also undertaken and estimates  
27  
28  
29 compared for: i) complete case analysis; and, ii) where missing data were coded as 'missing'  
30  
31  
32  
33  
34 categories. All analyses were performed using Stata/MP 17.0 (StataCorp LLC, USA).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

### *Patient Characteristics*

Baseline characteristics of each of the cohorts are shown in Table 1, and sub-grouped by type of musculoskeletal pain within each cohort in Supplementary Tables S1-5, available at *Rheumatology Advances in Practice* online. Size of population ranged from 128,649 (stroke) to 406,289 (cancer). Between 22% and 31% of patients had a consultation for one of the painful musculoskeletal conditions in the 24 months prior to the index date. Regional pain was the most common (12-17%) followed by OA (6-10%) and inflammatory arthritis (4-5%).

In all cohorts apart from dementia, those with OA (median 74-81 years) or inflammatory arthritis (75-80 years) were older than those with regional pain (69-77 years) or no musculoskeletal pain (69-77 years; Supplementary Tables S1-5). Prevalence of comorbidities and counts of prescribed medications were also generally higher for those with musculoskeletal pain compared to those without musculoskeletal pain. Those with musculoskeletal pain were more commonly ex-smokers and recorded as overweight or obese than those without musculoskeletal pain, and there were fewer men recorded with regional pain or OA in all cohorts apart from ACS (Supplementary Tables S1-5).

1  
2  
3 In the ACS cohort, there was a higher rate of mortality for all three musculoskeletal types.  
4  
5  
6 Patients with pre-existing inflammatory arthritis had the highest rate (92 per 1,000 person years  
7  
8  
9  
10 (py), unadjusted HR vs no pre-existing musculoskeletal pain 1.51; 95% CI 1.47, 1.56), followed  
11  
12  
13 by OA (77/1,000py; 1.27; 1.23, 1.30). In those without musculoskeletal pain rate of mortality was  
14  
15  
16 61/1,000py, and with regional pain it was 59/1000py (Table 2). There were also higher  
17  
18  
19 unadjusted rates of mortality in patients with pre-existing inflammatory arthritis compared to  
20  
21  
22 those without pre-existing musculoskeletal pain in the stroke (114 vs 95/1000py), cancer (186  
23  
24  
25 vs 145/1000py), and dementia (241 vs 222/1000py) cohorts and for patients with OA in the  
26  
27  
28 stroke (106 vs 95/1000py) and cancer (164 vs 145/1000py) cohorts. Patients newly diagnosed  
29  
30  
31 with cancer with regional pain (160/1000py) had higher unadjusted rates of mortality than those  
32  
33  
34 with no musculoskeletal pain. There was no evidence of increased mortality in those with  
35  
36  
37 musculoskeletal pain in the pneumonia cohort.  
38  
39  
40

41  
42 Most covariates did not change the associations found in the unadjusted analyses. However,  
43  
44  
45 the number of prescribed medications, and to a lesser extent, age did impact on the  
46  
47  
48 associations and the increased risk of mortality remained only for patients with inflammatory  
49  
50  
51 arthritis in the ACS cohort (adjusted HR 1.07; 95% CI 1.03, 1.10) after adjusting for these  
52  
53  
54 covariates (Table 2). Table 3 shows the number of different medications prescribed during the  
55  
56  
57  
58  
59  
60



1  
2  
3 baseline period with the highest counts in those with inflammatory arthritis. Associations of  
4  
5  
6 musculoskeletal pain with mortality were generally consistent at 2, 5 and 10-years of follow-up.  
7  
8

9  
10 In the secondary analysis, when assessing association of mortality with recency and severity of  
11  
12 musculoskeletal condition, the patients with current-severe musculoskeletal pain had the  
13  
14 highest rates of mortality for the ACS, cancer and dementia cohorts and the lowest for  
15  
16 pneumonia (Table 4). As with the primary analysis, adjustment for number of prescribed  
17  
18 medications had the greatest impact on observed associations and current-severe pain was  
19  
20 only associated with an increased adjusted risk of mortality in patients with cancer (adjusted HR  
21  
22 vs no musculoskeletal pain 1.25; 95% 1.21, 1.29)  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 33 *Sensitivity Analyses* 34

35  
36  
37 Similar estimates were obtained using the different approaches to account for missing data and  
38  
39  
40 did not change the study findings (data not shown).  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

To our knowledge this is the first study to explore whether pre-existing musculoskeletal pain impacts on the prognosis following incident ACS, stroke, cancer, dementia or community acquired pneumonia through increased rates of mortality. This study has shown increased rates of mortality across four common chronic conditions (ACS, stroke, cancer, dementia) for people with pre-existing musculoskeletal pain. This is particularly evident for those with inflammatory arthritis. However, after adjustment for number of prescribed medications and age, the majority of these associations were not maintained. These findings persisted in the secondary analysis which focussed on the recency of consultation and severity of pain rather than the type of musculoskeletal condition.

Musculoskeletal pain is highly prevalent as evidenced by up to a third of people newly diagnosed with ACS, stroke, cancer, dementia, and pneumonia having consulted for such a problem in the previous two years. It is also disabling and can have a major impact on everyday life, reducing the ability to perform everyday tasks and impacting on sleep, mental health, and work. Musculoskeletal pain is often neglected when a patient has co-occurring conditions, and its presence may be unrecognised or inadequately addressed (27,28), with the non-musculoskeletal conditions prioritised due to a perception of greater influence on mortality,

1  
2  
3 morbidity, and healthcare use. For example, research has highlighted that people living with  
4  
5  
6 dementia are less likely to have recorded primary care consultation or analgesics prescription  
7  
8  
9 for musculoskeletal conditions compared to those without dementia.(29) Despite previously  
10  
11  
12 observed associations of musculoskeletal pain with onset of clinical conditions (3–12) there is  
13  
14  
15 little prior evidence of its impact on outcomes of these conditions. The limited number of  
16  
17  
18 previous studies assessing the impact of musculoskeletal conditions on mortality have given  
19  
20  
21 mixed findings and tended to be small and/or based outside of the UK. To our knowledge this is  
22  
23  
24 the first study to explore whether pre-existing musculoskeletal pain impacts on the long-term  
25  
26  
27 prognosis following incident ACS, stroke, cancer, dementia or community acquired pneumonia  
28  
29  
30 through increased rates of mortality. Studies have shown inconsistent associations of  
31  
32  
33 inflammatory arthritis with in-hospital mortality in patients with ACS and stroke (16–18,30).  
34  
35  
36 Mobility impairment was associated with mortality in pneumonia in a study in Portugal.(31)  
37  
38  
39  
40  
41  
42 Patients with musculoskeletal pain, particularly inflammatory arthritis and OA do have an  
43  
44  
45 increased risk of earlier mortality. This is partly explained by being older but in addition the  
46  
47  
48 observed associations seemed to also be explained by increased polypharmacy in patients with  
49  
50  
51 musculoskeletal pain. This is consistent with our previous study looking at short term (30-day)  
52  
53  
54 outcomes in patients with a new ACS or stroke (32). In the current study, we found that patients  
55  
56  
57  
58  
59  
60

1  
2  
3 with musculoskeletal pain were being prescribed an average of 13-19 different medicines over  
4  
5  
6 two years. This excluded prescribed painkillers and “over the counter” medicines, so the overall  
7  
8  
9 number of medicines is likely to be higher. Whilst we also adjusted for specific comorbidities,  
10  
11  
12 this may reflect a higher multimorbidity load and increased frequency of consultation in such  
13  
14  
15 patients. Taking a high number of medicines has been associated with poor adherence  
16  
17  
18 especially when more than nine medications were prescribed and may in itself affect disease  
19  
20  
21 outcomes and disease progression.(33) A further concern is the possibility of inappropriate  
22  
23  
24 prescribing, with specific medicines increasing risk of poor outcome, for example increasing  
25  
26  
27 risks of falls, episodes of delirium, and hospital admissions because of adverse drug reactions.  
28  
29  
30  
31  
32 Further research is needed to understand more about the impact of multiple medications across  
33  
34  
35 common conditions.  
36  
37  
38

39 Whilst this study suggests musculoskeletal pain does not directly cause poorer outcomes, it  
40  
41  
42 highlights that musculoskeletal pain may be an indicator that patients may be more complex,  
43  
44  
45 being more likely to be older and have more comorbidities and medications. There is potential  
46  
47  
48 for pain and restricted functioning and mobility resulting from a musculoskeletal condition to  
49  
50  
51 affect delivery and effectiveness of treatment and rehabilitation. Improving musculoskeletal pain  
52  
53  
54 recognition and management, including integration within rehabilitation, may help improve its  
55  
56  
57  
58  
59  
60

1  
2  
3 impact on everyday life in people across co-occurring conditions and their outcomes. Clinicians  
4  
5  
6 need to think about the patient as a whole when treating individual illnesses including  
7  
8  
9  
10 consideration of all their illnesses and current medicines, and this study highlights the  
11  
12  
13 importance of regular medicine reviews.  
14  
15

### 16 *Strengths/Limitations*

17  
18  
19  
20 The study was set in a database of routinely recorded primary care data currently including 20%  
21  
22  
23 of the England population, which is nationally representative and was linked to secondary care  
24  
25  
26 and mortality information. Recorded morbidities in UK databases such as CPRD have shown  
27  
28  
29 high validity (34,35).  
30  
31  
32

33  
34 Some patients may not have had pain at time of the onset of the new condition. Therefore, in  
35  
36  
37 secondary analysis we also examined those with a more recent (last six months) consultation to  
38  
39  
40 reflect increased likelihood of a current episode of pain. As expected, those with a more recent  
41  
42  
43 consultation necessitating onward referral or prescription of a strong analgesic had increased  
44  
45  
46 risk of mortality but again that association tended to disappear when adjusting for number of  
47  
48  
49 medications. Defining musculoskeletal pain by consultation to primary care suggests the  
50  
51  
52 musculoskeletal pain was of a severity which prompted the need to seek healthcare, however  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 there will be patients in the non-musculoskeletal comparison group who have musculoskeletal  
4  
5  
6 pain without recently seeking healthcare. This is a limitation of research using such databases  
7  
8  
9  
10 and future research could evaluate impact of self-reported musculoskeletal pain on mortality.

11  
12  
13 However, the subgroup of patients with musculoskeletal pain who have not consulted for two  
14  
15  
16 years are likely to have less severe or less chronic pain. We restricted analysis to the most  
17  
18  
19 common painful conditions and those previously shown to be associated with the onset of our  
20  
21  
22 index conditions, and also adjusted for consultation for other musculoskeletal conditions.

23  
24  
25 Severity of pain is not recorded in electronic health records, and we therefore used surrogates  
26  
27  
28 for this, including onward referral to relevant specialists or prescription of a strong opioid  
29  
30  
31 analgesic (which cannot be bought over the counter). There may also be unmeasured  
32  
33  
34 confounding.

### 35 36 37 38 39 *Conclusion*

40  
41  
42 Musculoskeletal pain is common and a frequent reason for seeking health care within primary  
43  
44  
45 care. Older adults with inflammatory arthritis and OA often have co-existing illnesses and are on  
46  
47  
48 multiple medicines. As a consequence, when they have a new illness, they may be more likely  
49  
50  
51 to have poorer outcomes such as mortality compared to those without musculoskeletal pain.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Pre-existing musculoskeletal pain may be an indicator of a complex patient who is at risk of  
4  
5  
6 poorer outcomes at the onset of a new illnesses.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgments

CPRD: This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the authors alone.

ONS Data: The interpretation and conclusions contained in this study are those of the authors alone.

HES Data/ONS Data: Copyright © 2020, re-used with the permission of The Health & Social Care Information Centre. All rights reserved.

ISAC reference: The study was approved by the CPRD Independent Scientific Advisory Committee (refs 20\_000105; 20\_000147; 21\_000504; 21\_000689). The approved protocols were made available to reviewers.

PPIE/Advisory group: The authors would especially like to thank the members of the Keele Research User Group for their valuable contributions to this study. We are also thankful to Keele PPIE team for their support of the public contributors. The authors would also like to thank the project advisory group for the study.



## Funding statement

This project was funded by the Nuffield Foundation (OBF/43974). The Nuffield Foundation is an independent charitable trust with a mission to advance social well-being. It funds research that informs social policy, primarily in Education, Welfare, and Justice. It also funds student programmes that provide opportunities for young people to develop skills in quantitative and scientific methods. The Nuffield Foundation is the founder and co-funder of the Nuffield Council on Bioethics and the Ada Lovelace Institute. The Foundation has funded this project, but the views expressed are those of the authors and not necessarily the Foundation. Visit

[www.nuffieldfoundation.org](http://www.nuffieldfoundation.org)

KJM, KPJ and CDM are supported by matched funding awarded to the NIHR Applied Research Collaboration West Midlands. CDM is also funded by the NIHR School for Primary Care Research.

## Conflicts of Interest

The Keele School of Medicine have received funding from Bristol Myers Squibb for a non-pharmacological atrial fibrillation screening trial. The authors have no further conflicts to declare.

## Data Availability Statement

1  
2  
3 Data may be obtained from a third party and are not publicly available. The data were obtained  
4  
5  
6 from the Clinical Practice Research Datalink. Clinical Practice Research Datalink data  
7  
8  
9 governance does not allow us to distribute patient data to other parties. Researchers may apply  
10  
11  
12 for data access at <http://www.CPRD.com/>.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Jordan KP, Jód A, Bergknut C, Croft P, Edwards JJ, Peat G, et al. International comparisons of the consultation prevalence of musculoskeletal conditions using population-based healthcare data from England and Sweden. *Ann Rheum Dis*. 2014 Jan;73(1):212–8.
2. Kassebaum NJ, Arora M, Barber RM, Brown J, Carter A, Casey DC, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1603–58.
3. Wang H, Bai J, He B, Hu X, Liu D. Osteoarthritis and the risk of cardiovascular disease: A meta-analysis of observational studies. *Sci Rep*. 2016 Dec 22;6.
4. Hsu PS, Lin HH, Li CR, Chung WS. Increased risk of stroke in patients with osteoarthritis: a population-based cohort study. *Osteoarthr Cartil*. 2017 Jul 1;25(7):1026–31.
5. Williams A, Kamper SJ, Wiggers JH, O'Brien KM, Lee H, Wolfenden L, et al. Musculoskeletal conditions may increase the risk of chronic disease: A systematic review and meta-analysis of cohort studies. Vol. 16, *BMC Medicine*. BioMed Central; 2018.
6. Holmqvist M, Ljung L, Askling J. Acute coronary syndrome in new-onset rheumatoid arthritis: A population-based nationwide cohort study of time trends in risks and excess risks. *Ann Rheum Dis*. 2017 Oct 1;76(10):1642–7.
7. Nikiphorou E, De Lusignan S, Mallen CD, Khavandi K, Bedarida G, Buckley CD, et al. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: A population-based study. *Heart*. 2020 Oct 1;106(20):1566–72.
8. Jamnitski A, Symmons D, Peters MJL, Sattar N, McIlInnes I, Nurmohamed MT. Cardiovascular

- 1  
2  
3 comorbidities in patients with psoriatic arthritis: A systematic review. *Ann Rheum Dis*. 2013  
4  
5 Feb;72(2):211–6.  
6  
7
- 8 9. Fernandez M, Ordoñana JR, Hartvigsen J, Ferreira ML, Refshauge KM, Sánchez-Romera JF, et al. Is  
9  
10 chronic low back pain associated with the prevalence of coronary heart disease when genetic  
11  
12 susceptibility is considered? A co-twin control study of Spanish twins. *PLoS One*. 2016 May  
13  
14 1;11(5):e0155194.  
15  
16
- 17 10. Wang HC, Su YC, Luk HN, Wang JH, Hsu CY, Lin SZ. Increased risk of strokes in patients with  
18  
19 chronic low back pain (CLBP): A nationwide population-based cohort study. *Clin Neurol*  
20  
21 *Neurosurg*. 2020 May 1;192:105725.  
22  
23
- 24 11. Jordan KP, Hayward RA, Blagojevic-Bucknall M, Croft P. Incidence of prostate, breast, lung and  
25  
26 colorectal cancer following new consultation for musculoskeletal pain: A cohort study among UK  
27  
28 primary care patients. *Int J Cancer*. 2013 Aug 1;133(3):713–20.  
29  
30
- 31 12. Hagberg KW, Li L, Peng M, Paris M, Shah K, Jick SS. Rates of Cancers and Opportunistic Infections  
32  
33 in Patients With Psoriatic Arthritis Compared With Patients Without Psoriatic Arthritis. *J Clin*  
34  
35 *Rheumatol*. 2016;22(5):241–7.  
36  
37
- 38 13. Muller S, Hider SL, Belcher J, Helliwell T, Mallen CD. Is cancer associated with polymyalgia  
39  
40 rheumatica? A cohort study in the General Practice Research Database. *Ann Rheum Dis*.  
41  
42 2014;73(10):1769–73.  
43  
44
- 45 14. Weber A, Mak SH, Berenbaum F, Sellam J, Zheng Y-P, Han Y, et al. Association between  
46  
47 osteoarthritis and increased risk of dementia: A systemic review and meta-analysis. *Medicine*  
48  
49 (Baltimore). 2019 Mar;98(10):e14355.  
50  
51
- 52 15. Chung HY, Tam LS, Chan SCW, Cheung JPY, Wong PY, Ciang CO, et al. Risk of community-acquired  
53  
54 pneumonia requiring hospitalization in patients with spondyloarthritis. *Ther Adv Musculoskelet*  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Dis. 2020;12:1759720X20962618.  
4  
5  
6 16. Lai CH, Lai CH, Lai CH, Hsieh CY, Barnado A, Huang LC, et al. Outcomes of acute cardiovascular  
7 events in rheumatoid arthritis and systemic lupus erythematosus: A population-based study.  
8 Rheumatol (United Kingdom). 2020 Jun 1;59(6):1355–63.  
9  
10  
11  
12  
13 17. Isogai T, Matsui H, Tanaka H, Yokogawa N, Fushimi K, Yasunaga H. Treatments and in-hospital  
14 mortality in acute myocardial infarction patients with rheumatoid arthritis: a nationwide  
15 retrospective cohort study in Japan. Clin Rheumatol. 2017;36(5):995–1004.  
16  
17  
18  
19  
20 18. Kang JH, Xirasagar S, Lin HC, Kao PF, Sung LC. Risk of adverse outcomes in patients with  
21 rheumatoid arthritis hospitalized for stroke—a cross-sectional study. Clin Rheumatol. 2018 Nov  
22 1;37(11):2917–26.  
23  
24  
25  
26  
27 19. Francis ML, Varghese JJ, Mathew JM, Koneru S, Scaife SL, Zahnd WE. Outcomes in patients with  
28 rheumatoid arthritis and myocardial infarction. Am J Med. 2010;123(10):922–8.  
29  
30  
31  
32 20. Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource profile: Clinical  
33 Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019 Dec 1;48(6):1740-1740G.  
34  
35  
36  
37 21. CPRD. Release Notes: CPRD Aurum June 2021 [Internet]. 2021 [cited 2023 May 15]. Available  
38 from: <https://doi.org/10.48329/pyc2-we97>  
39  
40  
41  
42 22. CPRD. Release Notes: CPRD Aurum November 2021 [Internet]. 2021 [cited 2023 May 15].  
43 Available from: <https://doi.org/10.48329/hq9t-em88>  
44  
45  
46  
47 23. Burton C, Campbell P, Jordan K, Strauss V, Mallen C. The association of anxiety and depression  
48 with future dementia diagnosis: A case-control study in primary care. Fam Pract. 2013  
49 Feb;30(1):25–30.  
50  
51  
52  
53  
54 24. Jordan KP, Timmis A, Croft P, Van Der Windt DA, Denaxas S, González-Izquierdo A, et al.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Prognosis of undiagnosed chest pain: Linked electronic health record cohort study. *BMJ*. 2017  
4  
5 Apr 3;357:1194.  
6  
7
- 8 25. Marshall M, Mason K, Bailey J, Heron N, Achana F, Chen Y, et al. The impact of musculoskeletal  
9 conditions on outcomes of other illnesses (the MSKCOM study): a linked electronic health record  
10 study - Code lists. Bailey J, editor.  
11  
12  
13  
14
- 15 26. Bedson J, Belcher J, Martino OI, Ndlovu M, Rathod T, Walters K, et al. The effectiveness of  
16 national guidance in changing analgesic prescribing in primary care from 2002 to 2009: An  
17 observational database study. *Eur J Pain (United Kingdom)*. 2013 Mar;17(3):434–43.  
18  
19  
20  
21
- 22 27. Paskins Z, McHugh G, Hassell AB. Getting under the skin of the primary care consultation using  
23 video stimulated recall: A systematic review. *BMC Med Res Methodol*. 2014 Aug 30;14(1):1–18.  
24  
25  
26
- 27 28. OA Nation 2012 report by Arthritis Care [Internet]. [cited 2021 Jul 5]. Available from:  
28 [https://issuu.com/arthritiscare/docs/oa\\_nation\\_2012\\_report](https://issuu.com/arthritiscare/docs/oa_nation_2012_report)  
29  
30  
31
- 32 29. Bullock L, Bedson J, Chen Y, Chew-Graham CA, Campbell P. Comparative differences in  
33 musculoskeletal pain consultation and analgesic prescription for people with dementia: a UK-  
34 wide matched cohort study. *Pain*. 2021 Oct;162(10):2613–20.  
35  
36  
37  
38
- 39 30. McCoy SS, Crowson CS, Maradit-Kremers H, Therneau TM, Roger VL, Matteson EL, et al.  
40 Longterm outcomes and treatment after myocardial infarction in patients with rheumatoid  
41 arthritis. *J Rheumatol*. 2013;40(5):605–10.  
42  
43  
44  
45
- 46 31. Hespanhol V, Bárbara C. Pneumonia mortality, comorbidities matter? *Pulmonology*.  
47 2020;26(3):123–9.  
48  
49  
50  
51
- 52 32. Mason KJ, Jordan KP, Heron N, Edwards JJ, Bailey J, Achana FA, et al. Musculoskeletal pain and its  
53 impact on prognosis following acute coronary syndrome or stroke: A linked electronic health  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 record cohort study. *Musculoskeletal Care*. 2023;  
4  
5  
6 33. Smaje A, Weston-Clark M, Raj R, Orlu M, Davis D, Rawle M. Factors associated with medication  
7 adherence in older patients: A systematic review. *Aging Med (milt)*. 2018 Dec;1(3):254–66.  
8  
9  
10  
11 34. Persson R, Sponholtz T, Vasilakis-Scaramozza C, Hagberg KW, Williams T, Kotecha D, et al. Quality  
12 and completeness of myocardial infarction recording in clinical practice research datalink aurum.  
13 *Clin Epidemiol*. 2021;13:745–53.  
14  
15  
16  
17  
18 35. Herrett E, Shah ADA, Boggon R, Denaxas S, Smeeth L, Van Staa T, et al. Completeness and  
19 diagnostic validity of recording acute myocardial infarction events in primary care, hospital care,  
20 disease registry, and national mortality records: cohort study. *Bmj*. 2013 May  
21 25;346(7909):f2350.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 - Patient Characteristics by Cohort

	ACS	Stroke	Cancer	Dementia	Pneumonia
Total, n	165,350	128,649	406,289	199,961	192,587
Type of MSK Pain, n (%)					
No MSK Pain	116,231 (70)	89,949 (70)	291,256 (72)	137,042 (69)	149,871 (78)
Regional Pain	27,344 (17)	20,799 (16)	68,339 (17)	33,783 (17)	23,352 (12)
OA	12,863 (8)	10,966 (9)	30,451 (7)	19,941 (10)	10,989 (6)
Inflammatory	8,912 (5)	6,935 (5)	16,243 (4)	9,195 (5)	8,375 (4)
Recency and severity of MSK Pain, n (%)					
No MSK Pain	116,231 (70)	89,949 (70)	291,256 (72)	137,042 (69)	149,871 (78)
Recent	29,198 (18)	23,065 (18)	66,327 (16)	38,294 (19)	25,756 (13)
Current-non-severe	10,960 (7)	8,829 (7)	25,599 (6)	14,864 (7)	8,794 (5)
Current-severe	8,961 (5)	6,806 (5)	23,107 (6)	9,761 (5)	8,166 (4)
Median follow-up, years (IQR)	4.9 (2.0, 9.3)	3.6 (1.5, 7.1)	3.3 (1.1, 7.7)	4.6 (2.5, 7.9)	4.6 (3.4, 6.0)
Median age, years (IQR)	70 (60, 79)	75 (66, 83)	70 (62, 78)	83 (77, 87)	77 (65, 86)
Males, n (%)	106,500 (64)	66,639 (52)	202,451 (50)	77,253 (39)	94,318 (49)
Smoking Status, n (%) <sup>b</sup>					
Current smoker	44,548 (27)	28,216 (22)	89,114 (22)	28,972 (14)	33,000 (17)
Ex-smoker	42,438 (26)	32,928 (26)	110,048 (27)	57,646 (29)	46,930 (24)
Never Smoked/not recorded	78,364 (47)	67,505 (52)	207,127 (51)	113,343 (57)	112,657 (59)
Body Mass Index, n (%) <sup>b</sup>					
Underweight (10.0-18.0 kg/m <sup>2</sup> )	2,157 (1)	2,461 (2)	7,153 (2)	9,052 (5)	7,069 (4)
Normal/not recorded (18.0-<25.0 kg/m <sup>2</sup> )	86,554 (52)	69,684 (54)	203,223 (50)	107,742 (53)	116,502 (61)
Overweight (25.0-<30.0 kg/m <sup>2</sup> )	47,670 (29)	35,129 (27)	135,295 (33)	61,901 (31)	43,143 (22)
Obese (30.0-79.9 kg/m <sup>2</sup> )	28,969 (18)	21,375 (17)	60,618 (15)	21,266 (11)	25,873 (13)
Index of Multiple Deprivation Quintiles, n (%) <sup>a</sup>					
Least deprived/not recorded	34,116 (21)	27,574 (21)	100,377 (25)	44,371 (22)	36,421 (19)
Second-least deprived	34,193 (21)	27,205 (21)	91,009 (22)	43,364 (22)	36,082 (19)
Mid deprived	32,913 (20)	26,306 (20)	80,674 (20)	39,971 (20)	37,354 (19)
Second-most deprived	32,048 (19)	24,078 (19)	70,508 (17)	37,052 (19)	38,935 (20)
Most deprived	32,080 (19)	23,486 (18)	63,721 (16)	35,203 (18)	43,795 (23)
White /not recorded race, n (%) <sup>b</sup>	154,740 (94)	121,323 (94)	389,089 (96)	189,647 (95)	179,253 (93)
Specific comorbid conditions, n (%) <sup>a</sup>					
Diabetes	30,557 (18)	23,491 (18)	43,940 (11)	33,266 (17)	21,578 (11)
Peripheral Vascular Disease	5,183 (3)	3,622 (3)	N/A	N/A	N/A
Depression, Anxiety or Stress	12,937 (8)	10,258 (8)	52,341 (13)	26,095 (13)	12,955 (7)
Other MSK consultation	46,224 (28)	36,140 (28)	24,487 (6)	61,287 (31)	42,678 (22)
Renal Disease	N/A	N/A	14,353 (4)	N/A	6,394 (3)
Stroke	N/A	N/A	N/A	15,501 (8)	5,154 (3)
COPD/asthma	N/A	N/A	N/A	N/A	27,637 (14)
Dementia	N/A	N/A	N/A	N/A	11,131 (6)
Median number of prescriptions (IQR) <sup>a</sup>	9 (4, 16)	11 (6, 18)	9 (5, 16)	12 (7, 19)	9 (0, 18)
Prescribed statins, n (%) <sup>a</sup>	61,787 (37)	47,122 (37)	N/A	N/A	N/A



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Prescribed antibiotic, n (%)	N/A	N/A	N/A	N/A	20,044 (10)
------------------------------	-----	-----	-----	-----	-------------

Abbreviations: acute coronary syndrome (ACS); musculoskeletal (MSK); osteoarthritis (OA); interquartile range (IQR). <sup>a</sup> recorded in 24 months prior to index date; <sup>b</sup> recorded in 60 months prior to index date.

Downloaded from <https://academic.oup.com/rheumap/advance-article/doi/10.1093/rap/rkad104/7450129> by Keele University user on 11 December 2023

Table 2 – Association of mortality with type of musculoskeletal pain by cohort

	Rate per 1000py	Unadjusted HR (95% CI)	Adjusted <sup>a</sup> HR (95% CI)	Adjusted <sup>b</sup> HR (95% CI)	Adjusted <sup>c</sup> HR (95% CI)
<b>ACS</b>					
No MSK Pain	61 (61, 62)	1	1	1	1
Regional Pain	59 (58, 60)	0.98 (0.95, 1.00)	0.95 (0.93, 0.97)	0.81 (0.79, 0.83)	0.90 (0.88, 0.92)
OA	77 (75, 79)	1.27 (1.23, 1.30)	0.90 (0.87, 0.92)	0.98 (0.95, 1.01)	0.85 (0.83, 0.88)
Inflammatory	92 (89, 95)	1.51 (1.47, 1.56)	1.18 (1.14, 1.21)	1.12 (1.08, 1.16)	1.07 (1.03, 1.10)
<b>Stroke</b>					
No MSK Pain	95 (94, 96)	1	1	1	1
Regional Pain	88 (86, 90)	0.93 (0.91, 0.95)	0.92 (0.90, 0.95)	0.81 (0.79, 0.83)	0.90 (0.88, 0.92)
OA	106 (103, 109)	1.12 (1.09, 1.15)	0.90 (0.88, 0.92)	0.94 (0.91, 0.97)	0.86 (0.84, 0.89)
Inflammatory	114 (110, 118)	1.21 (1.17, 1.25)	1.08 (1.05, 1.12)	0.98 (0.95, 1.02)	1.00 (0.97, 1.04)
<b>Cancer</b>					
No MSK Pain	145 (144, 146)	1	1	1	1
Regional Pain	160 (158, 162)	1.09 (1.07, 1.10)	1.09 (1.07, 1.10)	0.98 (0.96, 1.00)	1.00 (0.98, 1.01)
OA	164 (161, 167)	1.10 (1.07, 1.13)	0.98 (0.95, 1.00)	0.94 (0.92, 0.97)	0.91 (0.89, 0.93)
Inflammatory	186 (182, 190)	1.24 (1.20, 1.28)	1.11 (1.07, 1.14)	1.00 (0.97, 1.03)	0.97 (0.94, 1.00)
<b>Dementia</b>					
No MSK Pain	222 (221, 224)	1	1	1	1
Regional Pain	218 (216, 221)	1.01 (0.99, 1.03)	1.02 (1.00, 1.04)	0.93 (0.91, 0.95)	0.95 (0.93, 0.97)
OA	216 (212, 219)	0.98 (0.95, 1.01)	0.96 (0.93, 0.99)	0.89 (0.86, 0.91)	0.92 (0.89, 0.95)
Inflammatory	241 (235, 247)	1.16 (1.11, 1.21)	1.16 (1.11, 1.21)	1.01 (0.96, 1.05)	1.01 (0.97, 1.06)
<b>Pneumonia <sup>d</sup></b>					
No MSK Pain	127 (126, 128)	1	1	1	1
Regional Pain	105 (103, 108)	0.87 (0.85, 0.89)	0.86 (0.84, 0.88)	0.72 (0.71, 0.74)	0.86 (0.83, 0.88)
OA	107 (104, 111)	0.86 (0.83, 0.89)	0.73 (0.70, 0.75)	0.70 (0.67, 0.72)	0.75 (0.73, 0.78)
Inflammatory	125 (120, 130)	0.97 (0.93, 1.01)	0.86 (0.83, 0.90)	0.76 (0.73, 0.80)	0.83 (0.80, 0.87)

Abbreviations: acute coronary syndrome (ACS); musculoskeletal (MSK); osteoarthritis (OA); hazard ratio (HR); confidence interval (CI).

1  
2  
3 <sup>a</sup> adjusted for age; <sup>b</sup> adjusted for number of medications excluding analgesia; <sup>c</sup> adjusted for all covariates;

4  
5  
6 <sup>d</sup> mortality measured from index date to 12m.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 3 – Median (IQR) number of different medications prescribed at baseline excluding

analgesia

Cohort	No MSK pain	Regional pain	OA	Inflammatory
ACS	8 (3, 14)	11 (6, 18)	12 (7, 20)	14 (8, 22)
Stroke	8 (4, 14)	12 (7, 18)	13 (8, 19)	14 (9, 21)
Cancer	8 (4, 14)	12 (7, 18)	14 (8, 20)	15 (10, 22)
Dementia	11 (7, 17)	14 (9, 21)	15 (9, 21)	17 (11, 24)
Pneumoni	5 (0, 15)	17 (10, 25)	18 (12, 26)	19 (13, 27)

a

Table 4 – Association of mortality with recency and severity of musculoskeletal pain by cohort

	Rate per 1000py	Unadjusted HR (95% CI)	Adjusted <sup>a</sup> HR (95% CI)
ACS			
No MSK Pain	61 (61, 62)	1	1
Recent	66 (65, 68)	1.09 (1.07, 1.12)	0.91 (0.89, 0.93)
Current-non-severe	72 (70, 74)	1.18 (1.14, 1.22)	0.91 (0.89, 0.94)
Current-severe	76 (73, 78)	1.26 (1.22, 1.30)	0.97 (0.94, 1.01)
Stroke			
No MSK Pain	95 (94, 96)	1	1
Recent	96 (94, 98)	1.01 (0.99, 1.03)	0.91 (0.89, 0.93)
Current-non-severe	101 (98, 104)	1.06 (1.03, 1.10)	0.91 (0.88, 0.93)
Current-severe	96 (93, 100)	1.02 (0.98, 1.06)	0.90 (0.87, 0.93)
Cancer			
No MSK Pain	145 (144, 146)	1	1
Recent	157 (155, 159)	1.09 (1.08, 1.11)	0.96 (0.94, 0.97)
Current-non-severe	151 (148, 153)	1.07 (1.04, 1.09)	0.96 (0.93, 0.98)
Current-severe	216 (212, 220)	1.53 (1.48, 1.58)	1.25 (1.21, 1.29)
Dementia			
No MSK Pain	222 (221, 224)	1	1
Recent	219 (217, 222)	1.02 (1.00, 1.04)	0.96 (0.94, 0.98)
Current-non-severe	222 (218, 226)	1.02 (0.98, 1.05)	0.97 (0.93, 1.00)
Current-severe	224 (219, 230)	1.07 (1.02, 1.12)	0.97 (0.92, 1.01)
Pneumonia <sup>b</sup>			
No MSK Pain	127 (126, 128)	1	1
Recent	111 (109, 114)	0.90 (0.88, 0.92)	0.83 (0.81, 0.85)
Current-non-severe	130 (126, 135)	1.02 (0.98, 1.06)	0.86 (0.83, 0.89)
Current-severe	85 (81, 88)	0.71 (0.67, 0.74)	0.73 (0.70, 0.77)

Abbreviations: acute coronary syndrome (ACS); musculoskeletal (MSK); hazard ratio (HR); confidence interval (CI).

<sup>a</sup> adjusted for all covariates; <sup>b</sup> mortality measured from index date to 12m.